Overview Dividends

(CRI) Carter’s - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1462291097

Apparel,Infant,Children,Accessories

CRI EPS (Earnings per Share)

EPS Growth (3Y CAGR): -87.04%
EPS Trend (3Y Correlation): -54.7%

CRI Revenue

Revenue Growth (3Y CAGR): -11.48%
Revenue Trend (3Y Correlation): -42.6%

Description: CRI Carter’s

Carters Inc (NYSE:CRI) is a US-based company operating in the Apparel, Accessories & Luxury Goods sub-industry. The company designs, manufactures, and markets branded childrens apparel, accessories, and related products.

To evaluate CRIs investment potential, we need to examine key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of sales. A review of these metrics can help identify trends and areas for improvement. For instance, a stable or increasing gross margin indicates the companys ability to maintain pricing power and manage production costs.

Key economic drivers for CRI include consumer spending on childrens apparel, demographic trends such as birth rates and population growth, and competition from online retailers. The companys ability to adapt to changing consumer preferences and navigate the shift to e-commerce will be crucial to its long-term success.

CRIs current valuation multiples, including a P/E ratio of 6.74 and a forward P/E of 25.19, suggest a potentially undervalued stock with room for growth. The companys return on equity (RoE) of 16.38% indicates a relatively strong ability to generate profits from shareholder equity.

To further assess CRIs investment potential, we should analyze its financial statements to identify trends in cash flow generation, debt levels, and dividend sustainability. A thorough examination of these factors will help determine whether the companys current valuation is justified and whether its future prospects are promising.

CRI Stock Overview

Market Cap in USD	927m
Sub-Industry	Apparel, Accessories & Luxury Goods
IPO / Inception	2003-10-24

CRI Stock Ratings

Growth Rating	-79.3%
Fundamental	58.9%
Dividend Rating	66.4%
Return 12m vs S&P 500	-61.0%
Analyst Rating	2.33 of 5

CRI Dividends

Dividend Yield 12m	6.04%
Yield on Cost 5y	3.16%
Annual Growth 5y	39.77%
Payout Consistency	94.2%
Payout Ratio	43.4%

CRI Growth Ratios

Growth Correlation 3m	-64.9%
Growth Correlation 12m	-96%
Growth Correlation 5y	-80.5%
CAGR 5y	-15.60%
CAGR/Max DD 5y	-0.21
Sharpe Ratio 12m	-0.52
Alpha	-64.57
Beta	0.431
Volatility	58.51%
Current Volume	1050.3k
Average Volume 20d	1294.7k
Stop Loss	27.2 (-4.8%)
Signal	-0.64

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (135.6m TTM) > 0 and > 6% of Revenue (6% = 170.0m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -9.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 22.33% (prev 19.99%; Δ 2.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 198.8m > Net Income 135.6m (YES >=105%, WARN >=100%)

Net Debt (786.2m) to EBITDA (256.3m) ratio: 3.07 <= 3.0 (WARN <= 3.5)

Current Ratio 2.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (35.4m) change vs 12m ago -0.78% (target <= -2.0% for YES)

Gross Margin 47.29% (prev 48.43%; Δ -1.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 117.8% (prev 122.1%; Δ -4.29pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 6.43 (EBITDA TTM 256.3m / Interest Expense TTM 31.2m) >= 6 (WARN >= 3)

Altman Z'' 3.96

(A) 0.26 = (Total Current Assets 1.16b - Total Current Liabilities 525.7m) / Total Assets 2.46b

(B) 0.36 = Retained Earnings (Balance) 871.9m / Total Assets 2.46b

(D) 0.52 = Book Value of Equity 839.4m / Total Liabilities 1.60b

Total Rating: 3.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 58.89

1. Piotroski 4.0pt = -1.0

2. FCF Yield 11.59% = 5.0

3. FCF Margin 4.95% = 1.24

4. Debt/Equity 0.73 = 2.24

5. Debt/Ebitda 2.43 = -0.83

6. ROIC - WACC 7.05% = 8.81

7. RoE 16.02% = 1.34

8. Rev. Trend -42.57% = -2.13

9. Rev. CAGR -11.48% = -1.91

10. EPS Trend -54.65% = -1.37

11. EPS CAGR -87.04% = -2.50

What is the price of CRI shares?

As of September 01, 2025, the stock is trading at USD 28.56 with a total of 1,050,255 shares traded.
Over the past week, the price has changed by +9.66%, over one month by +12.66%, over three months by -9.75% and over the past year by -54.42%.

Is Carter’s a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Carter’s is currently (September 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 58.89 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CRI is around 23.76 USD . This means that CRI is currently overvalued and has a potential downside of -16.81%.

Is CRI a buy, sell or hold?

Carter’s has received a consensus analysts rating of 2.33. Therefor, it is recommend to sell CRI.

Strong Buy: 0
Buy: 0
Hold: 3
Sell: 2
Strong Sell: 1

What are the forecasts/targets for the CRI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	24.6	-13.9%
Analysts Target Price	29	1.5%
ValueRay Target Price	25.7	-10.2%

Last update: 2025-08-22 04:35

CRI Fundamental Data Overview

Market Cap USD = 926.8m (926.8m USD * 1.0 USD.USD)
CCE Cash And Equivalents = 338.2m USD (last quarter)
P/E Trailing = 6.784
P/E Forward = 25.3165
P/S = 0.3271
P/B = 1.0854
P/EG = 1.81
Beta = 0.987
Revenue TTM = 2.83b USD
EBIT TTM = 200.8m USD
EBITDA TTM = 256.3m USD
Long Term Debt = 498.5m USD (from longTermDebt, last quarter)
Short Term Debt = 124.0m USD (from shortTermDebt, last quarter)
Debt = 622.5m USD (Calculated: Short Term 124.0m + Long Term 498.5m)
Net Debt = 786.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.21b USD (926.8m + Debt 622.5m - CCE 338.2m)
Interest Coverage Ratio = 6.43 (Ebit TTM 200.8m / Interest Expense TTM 31.2m)
FCF Yield = 11.59% (FCF TTM 140.4m / Enterprise Value 1.21b)
FCF Margin = 4.95% (FCF TTM 140.4m / Revenue TTM 2.83b)
Net Margin = 4.79% (Net Income TTM 135.6m / Revenue TTM 2.83b)
Gross Margin = 47.29% ((Revenue TTM 2.83b - Cost of Revenue TTM 1.49b) / Revenue TTM)
Tobins Q-Ratio = 1.44 (Enterprise Value 1.21b / Book Value Of Equity 839.4m)
Interest Expense / Debt = 1.26% (Interest Expense 7.86m / Debt 622.5m)
Taxrate = 19.63% (from yearly Income Tax Expense: 45.3m / 230.8m)
NOPAT = 161.4m (EBIT 200.8m * (1 - 19.63%))
Current Ratio = 2.20 (Total Current Assets 1.16b / Total Current Liabilities 525.7m)
Debt / Equity = 0.73 (Debt 622.5m / last Quarter total Stockholder Equity 853.9m)
Debt / EBITDA = 2.43 (Net Debt 786.2m / EBITDA 256.3m)
Debt / FCF = 4.44 (Debt 622.5m / FCF TTM 140.4m)
Total Stockholder Equity = 846.3m (last 4 quarters mean)
RoA = 5.52% (Net Income 135.6m, Total Assets 2.46b )
RoE = 16.02% (Net Income TTM 135.6m / Total Stockholder Equity 846.3m)
RoCE = 14.93% (Ebit 200.8m / (Equity 846.3m + L.T.Debt 498.5m))
RoIC = 12.00% (NOPAT 161.4m / Invested Capital 1.34b)
WACC = 4.95% (E(926.8m)/V(1.55b) * Re(7.60%)) + (D(622.5m)/V(1.55b) * Rd(1.26%) * (1-Tc(0.20)))
Shares Correlation 5-Years: -90.0 | Cagr: -3.87%
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 75.77% ; FCFE base≈225.7m ; Y1≈193.0m ; Y5≈149.6m
Fair Price DCF = 75.07 (DCF Value 2.74b / Shares Outstanding 36.4m; 5y FCF grow -17.63% → 3.0% )
Revenue Correlation: -42.57 | Revenue CAGR: -11.48%
Rev Growth-of-Growth: 3.46
EPS Correlation: -54.65 | EPS CAGR: -87.04%
EPS Growth-of-Growth: -105.6

Additional Sources for CRI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle